Navigation Links
Arcturus Therapeutics to Present at the 19th Annual BIO CEO & Investor Conference
Date:2/9/2017

SAN DIEGO, Feb. 9, 2017 /PRNewswire/ -- Arcturus Therapeutics, Inc. ("Arcturus" or the "Company"), a leading RNA medicines company, today announced that President & CEO Joseph E. Payne will present a corporate update at the 2017 Annual BIO CEO & Investor Conference on Monday, February 13th at 1:00 p.m. ET in the Park North room at the Waldorf Astoria Hotel in New York City.

Arcturus has several partnered and fully funded RNA therapeutics in its pipeline (including HBV, NASH, and orphan diseases), and is appraising investors interested in the Company's wholly owned rare disease messenger RNA programs.  The management team will be available for one-on-one meetings with investors. To schedule a meeting, please use the BIO CEO One-on-One meeting portal.

About Arcturus Therapeutics, Inc.
Founded in 2013 and based in San Diego, Arcturus Therapeutics, Inc. is an RNA medicines company with enabling technologies — UNA Oligomer chemistry and LUNAR™ nanoparticle delivery. Arcturus' versatile RNA therapeutics platform can be applied toward all types of RNA medicines including small interfering RNA, messenger RNA, antisense RNA, microRNA and gene editing therapeutics. The company owns LUNAR™ nanoparticle delivery and unlocked nucleomonomer agent (UNA) technology including UNA Oligomers, which are covered by its patent portfolio (80 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus' proprietary UNA technology can be used to target any gene in the human genome, as well as viral genes, and other species for therapeutic purposes. The Company's commitment to the development of novel RNA therapeutics has led to significant partnerships with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., and Takeda Pharmaceutical Inc. For more information, visit www.ArcturusRx.com.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/arcturus-therapeutics-to-present-at-the-19th-annual-bio-ceo--investor-conference-300405446.html


'/>"/>
SOURCE Arcturus Therapeutics, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Arcturus Therapeutics, Inc. to Present at the Biotech Showcase 2014
2. Oxford BioTherapeutics Strengthens Board of Directors with Appointment of Two Biotech Veterans
3. Research Reports Coverage on Biotech Stocks -- Cerulean Pharma, AveXis, TG Therapeutics, and Aralez Pharma
4. PTC Therapeutics Announces Third Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy
5. Aratana Therapeutics to Attend North American Veterinary Conference
6. Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phase 2 Data Demonstrating 11-Month Duration-of-Action After a Single Dose in Patients With Glaucoma
7. Research Reports Coverage on Biotech Stocks -- Intercept Pharma, Aeterna Zentaris, Spark Therapeutics, and Aratana Therapeutics
8. Applied BioMath, LLC and CytomX Therapeutics, Inc. announce a collaboration to develop a Quantitative Systems Pharmacology Probody platform model for use in lmmuno-Oncology
9. Oxford Finance Provides $10 Million Senior Debt Facility to Oxford BioTherapeutics
10. Relmada Therapeutics to Provide an Update on the Development Plan for LevoCap ER
11. Aratana Therapeutics Named Animal Pharms Best Company in North America 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2019)... (PRWEB) , ... July 08, 2019 , ... Today, at ... Iowa, the National Corn Growers Association (NCGA) announced the winners of the ... improve a product or process using field corn to produce biobased materials. , “Corn ...
(Date:7/2/2019)... Calif. (PRWEB) , ... July 02, 2019 , ... Leading ... documentary entitled Animal Pharm: Where Beasts Meet Biotech. The film focuses on regenerative ... wild animals. Animal Pharm was recently included in the Brentwood and ...
(Date:6/18/2019)... ... June 17, 2019 , ... ... entered into an agreement for production and manufacturing of GMP-grade adeno-associated virus (AAV) ... rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for the treatment of BEST1 ...
(Date:6/12/2019)... HARBOR TOWNSHIP, N.J. (PRWEB) , ... June 12, ... ... manufacturer of custom built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, Medical ... agreement with Shanghai Zillion has been signed. The agreement will grant exclusive rights ...
Breaking Biology Technology:
(Date:7/17/2019)... ... July 16, 2019 , ... Imagine using a simple, portable test to ... before it causes osteoporosis. For South Dakota School of Mines & Technology researcher Congzhou ... in terms of our ability to monitor and prevent disease,” says Wang. , ...
(Date:7/9/2019)... ... July 09, 2019 , ... Murrieta ... into its incubator program. The founder and CEO of Tx Genetic, Helen Harrison, ... of those suffering from epithelial connective tissue disorders. , “We are pleased and ...
(Date:7/5/2019)... ... July 05, 2019 , ... ... bring its patented Tractus™ Platform to governments around the world. , Powered ... technology and point of care solutions to operating theatres worldwide to address new ...
Breaking Biology News(10 mins):